Study on the Expression and Clinical Pathological Characteristics of Serum NOP53 mRNA and FNDC1 mRNA in Patients with Locally Advanced Rectal Cancer and Their Value in Evaluating the Efficacy of Neoadjuvant Radiotherapy and Chemotherapy
10.3969/j.issn.1671-7414.2025.04.010
- VernacularTitle:局部晚期直肠癌患者血清NOP53 mRNA,FNDC1 mRNA表达与临床病理特征及其对新辅助放化疗疗效评估价值研究
- Author:
Xiaohui BAI
1
;
Ying WEI
;
Wangbin LI
;
Ning HE
;
Yuyao LI
;
Changtao ZHAO
Author Information
1. 西安交通大学第一附属医院榆林医院肿瘤放疗科,陕西 榆林 719000
- Publication Type:Journal Article
- Keywords:
rectal cancer;
ribosomal biogenesis factor nucleolar protein 53(NOP53);
fibronectin type Ⅲ domain containing 1;
neoadjuvant chemoradiotherapy
- From:
Journal of Modern Laboratory Medicine
2025;40(4):55-60
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the value of serum ribosomal biogenesis factor nucleolar protein53(NOP53)mRNA and fibronectin type Ⅲ domain containing 1(FNDC1)mRNA in evaluating the efficacy of neoadjuvant chemoradiotherapy(NACRT)in patients with locally advanced rectal cancer.Methods A total of 140 patients with locally advanced rectal cancer who received NACRT treatment in Yulin Hospital the First Affiliated Hospital of Xi'an Jiaotong University from January 2020 to January 2023 were selected as the study group.According to the efficacy of NACRT treatment,they were divided into good response group(99 cases)and poor response group(41 cases).At the same time,70 healthy people were selected as control group.Real-time fluorescence quantitative PCR was used to detect serum NOP53 mRNA and FNDC1 mRNA levels in the two groups.Logistic regression analysis was used to analyze the factors affecting the efficacy of NACRT.The value of serum NOP53 mRNA and FNDC1 mRNA in evaluating the efficacy of NACRT for rectal cancer was analyzed by receiver operating characteristic analysis.Results The expression of serum NOP53 mRNA(3.21±0.36)and FNDC1 mRNA(2.73±0.34)in the study group was higher than that in the control group(0.61±0.17,0.72±0.18),and the differences were statistically significant(t=57.267,46.287,all P<0.001).The expression of serum NOP53 mRNA(4.08±0.43,4.10±0.40)and FNDC1 mRNA(3.62±0.39,3.40±0.39)in patients with T stage T4 and N stage N1+N2 rectal cancer was higher than that in patients with T stage T3(2.52±0.30,2.02±0.29)and N stage N0(2.21±0.31,1.02±0.30),and the differences were statistically significant(t=25.241～40.106,all P<0.001).The proportion of T stage T4(73.17%),N stage N1+N2(75.61%),serum NOP53 mRNA(5.56±0.39)and FNDC1 mRNA(4.42±0.38)in the poor response group were higher than those in the good response group(32.32%,43.43%,2.24±0.31,2.03±0.29),and the differences were statistically significant(t=12.045～53.337,all P<0.001).T stage T4,N stage N1+N2,high serum NOP53 mRNA,high serum FNDC1 mRNA were risk factors affecting the efficacy of NACRT for rectal cancer(Wald χ2=9.463～15.589,all P<0.001).The AUC of serum NOP53 mRNA combined with FNDC1 mRNA in evaluating the efficacy of NACRT for rectal cancer higher than predicted by serum NOP53 mRNA and FNDC1 mRNA alone,and the differences were statistically significant(Z=4.645,4.321,all P<0.001).Conclusion The levels of serum NOP53 mRNA and FNDC1 mRNA in patients with locally advanced rectal cancer are increased,which are related to the poor clinicopathological features of patients.Combined with serum NOP53 mRNA,FNDC1 mRNA can effectively predict the clinical efficacy of NACRT in patients with rectal cancer.
